International Journal of Research and Review
[Indexed, Peer-Reviewed Journal]
Volume 12; Issue: 2; February 2025
Website: www.ijrrjournal.com
Review Article *E-ISSN: 2349-9788; P-ISSN: 2454-2237*

Consequences of Untreated Sleep Apnea on the Cardiovascular and Pulmonary Systems: A Systematic Review

Joseph White[1], Redah Essul[1], Gabriela Kennedy[1], Laxman Reddy Nadithe[2], Namani Satyanarayana[3], Paripelli Sunitha[3], Sreenivasa Gadireddy[3]

[1]MD-5 Students; Saint James School of Medicine, Arnos Vale, St. Vincent & the Grenadines
[2]Assistant Professor, Saint James School of Medicine, Arnos Vale, St. Vincent & the Grenadines
[3]Associate Professor, Saint James School of Medicine, Arnos Vale, St. Vincent & the Grenadines

Corresponding Author: Paripelli Sunitha

DOI: https://doi.org/10.52403/ijrr.20250245

ABSTRACT

Obstructive sleep apnea (OSA) is a prevalent disorder with significant implications for cardiovascular and pulmonary health. Despite the growing awareness of OSA, many cases remain untreated, leading to severe long-term health consequences. This systematic review synthesizes current evidence on the effects of untreated OSA on these critical systems, aiming to enhance clinical management and inform public health strategies. A comprehensive literature search was conducted, focusing on peer-reviewed studies published in the last 15 years. Findings underscore the exacerbation of cardiovascular diseases, increased pulmonary complications, and diminished quality of life due to untreated OSA. Addressing this knowledge gap is vital for reducing the societal and economic burdens associated with this disorder.

Keywords: Obstructive sleep apnea (OSA), cardiovascular, pulmonary health.

INTRODUCTION

Obstructive sleep apnea is increasingly recognized as a major public health concern due to its high prevalence and associated morbidity. OSA, which encompasses both the physiological manifestations of OSA and the resultant clinical consequences, can lead to severe health complications, including cardiovascular and pulmonary disease. Despite its significant impact, OSA remains underdiagnosed, with estimates suggesting that only 40% of affected individuals receive appropriate medical attention [1].

OSA is defined as a prevalent sleep disorder characterized by recurrent episodes of partial or complete cessation of breathing during sleep [1]. Untreated sleep apnea poses tremendous risks to an individual's cardiovascular and pulmonary health, with potentially severe long-term consequences [2]. While short-term effects of sleep apnea have been well documented, the literature lacks comprehensive examinations of its prolonged impacts on these body systems. This represents a critical knowledge gap, as many individuals with sleep apnea remain undiagnosed or do not receive adequate treatment.

The prevalence of OSA varies across populations, but studies indicate that approximately 24% of men and 9% of women in the United States have mild to severe forms of the condition, translating to an estimated 29.5 million adults over the age of 30 affected by OSA, with about 13 million suffering from moderate to severe cases

(apnea-hypopnea index (AHI) ≥ 15)[3]. The condition is particularly prevalent among individuals with comorbidities such as obesity, hypertension, and diabetes, further complicating its management and increasing the urgency for effective treatment strategies. The objective of this systematic review is to evaluate the consequences of untreated sleep apnea on the cardiovascular and respiratory systems. The overarching research question asks: what are the effects of sleep apnea on the cardiovascular and respiratory systems? Sleep apnea is a serious public health concern due to its high prevalence and potential to cause morbidity and mortality through associated comorbidities if left untreated [3]. Understanding its extended impacts is crucial for improving clinical management of the disorder and reducing the associated disease burden.

Studies have shown untreated obstructive sleep apnea syndrome can result in adverse physiological changes and elevated risk of cardiovascular diseases, stroke, metabolic disorders, excessive daytime fatigue, workplace incidents, traffic accidents, and even death [4]. These consequences place tremendous economic strain on society through increased healthcare utilization and lost productivity [5]. Identifying and appropriately treating sleep apnea has been demonstrated to significantly reduce both health and societal impacts as well as their costs [6]. However, existing research predominantly examines acute effects, while long-term cardiopulmonary implications remain poorly understood.

The current systematic review aims to address this important gap in knowledge. A comprehensive literature search will be conducted through relevant medical databases and pre-determined inclusion criteria applied. Outcome measures will include changes in biometric parameters, incidence of cardiovascular events, organ function, treatment responses, and quality of life indicators. Findings will provide valuable insights into prolonged consequences of untreated sleep apnea and inform strategies to enhance patient care and management of this widespread disorder. In summary, this review seeks to expand understanding of extended cardiopulmonary risks posed by untreated sleep apnea and their clinical and public health implications.

METHODS

To thoroughly investigate the long-term cardiopulmonary effects of untreated sleep apnea, we will conduct a systematic and comprehensive literature search using various resources. This will include the Saint James school of Medicine Library, PudMed, and several well-established electronic databases, including the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effectiveness (DARE), and the Campbell Collaboration Library of Systematic Reviews. These resources are widely recognized for their extensive collections of medical and scientific literature, offering non-peer-reviewed studies and systematic reviews that will support a robust analysis of existing research.

Specific search terms will be employed to identify studies pertinent to our research focus. These search terms will include “obstructive sleep apnea”, “Continuous positive airway pressure” (CPAP), “bilevel positive airway pressure” (BiPAP), “cardiovascular disease” and "pulmonary disease”. The Boolean operator “AND” will be used to link these terms and refine the search, ensuring that only studies directly relevant to sleep apnea and its treatment modalities are included. This search strategy is designed to capture the most relevant literature on the cardiopulmonary effects of untreated sleep apnea, with an emphasis on long-term consequences and outcomes.

Inclusion criteria for this systematic review have been carefully selected to ensure the relevance and quality of the studies reviewed. First, all sources must be scholarly or peer-reviewed, as this will ensure that the included studies meet rigorous academic standards. Second, we will limit the search to articles published within the last 15 years, ensuring that the review reflects the most

current knowledge and understanding of the topic. Third, only studies that present experimental or observational research in the field of medicine will be included, with a particular focus on human subjects rather than animal studies. Finally, all articles must be published in the English language to ensure a thorough and accurate analysis of the research.

The review will focus on various outcome measures important for understanding the long-term impacts of untreated sleep apnea. Key outcomes will include changes in blood pressure, which can serve as an indicator of cardiovascular stress, and the incidence of cardiovascular events, such as heart attacks or strokes, that are often linked to untreated sleep apnea [3,7]. Additionally, we will assess changes in cardiac function and the presence of biomarkers indicative of cardiovascular or pulmonary distress. Pulmonary function will also be evaluated to understand how untreated sleep apnea affects respiratory health over time. Beyond these physiological measures, the review will examine how untreated sleep apnea impacts patients' quality of life, comorbidities, and overall treatment outcomes, as well as any adverse events that may arise from the lack of treatment.

PATHOPHYSIOLOGICAL MECHANISMS

Obstructive sleep apnea can precipitate, perpetuate, or exacerbate an array of cardiovascular afflictions, including hypertension, coronary artery disease, arrhythmias, stroke, and heart failure [8]. This is attributed to the convergence of mechanical, autonomic, chemical, and inflammatory mechanisms that disrupt normal sleep patterns and the circadian synchronization of cardiac metabolic processes. During undisturbed sleep, blood pressure and heart rate typically decline by 25% or more, as central sympathetic outflow diminishes and vagal tone increases [9]. In contrast, OSA bombards the cardiovascular system with a barrage of detrimental stimuli at a time when the heart is metabolically ill-equipped to cope.

Sleep-related collapse of the airway triggers apnea, eliciting an abrupt inspiratory effort. With the airway obstructed, this generates a sudden spike in negative intrathoracic pressure, augmenting left ventricular transmural pressure, left atrial wall tension, and venous return to the right ventricle [6,10]. The resulting leftward shift of the interventricular septum impairs left ventricular filling and reduces stroke volume. With airflow halted, these adverse loading conditions persist, culminating in myocardial oxygen supply-demand mismatch and sympathetic excitation. Arousal from sleep heightens sympathetic nerve discharge and blunts vagal tone, acutely elevating heart rate and blood pressure [11,12].

In susceptible hearts, this acute imbalance between oxygen supply and demand can provoke ischemia or arrhythmia [13]. Chronically, the nightly surges in ventricular afterload and blood pressure may engender hypertension, hypertrophy, or dilation. The imposed oxidative stress also predisposes patients to atherosclerosis and cerebrovascular disease [10,14]. Additionally, there are similar increases in carotid intima-media thickness in carefully matched subjects with either OSA or hypertension, and even greater pathology in those afflicted by both conditions. Furthermore, severe OSA has been linked to heightened long-term risk of ischemic stroke in men[15].

The deleterious impacts of OSA on the cardiovascular system are multifaceted and interconnected. The recurrent episodes of airway obstruction, hypoxia, and arousals from sleep trigger a cascade of neurohumoral, metabolic, and inflammatory changes that cumulatively place the heart and vascular system under immense stress [16,17].

The intermittent hypoxia characteristic of OSA has been demonstrated to induce oxidative stress, endothelial dysfunction, and inflammation - key drivers of atherosclerosis. OSA patients exhibit higher circulating levels of pro-atherogenic molecules such as C-reactive protein, tumor

necrosis factor-α, and interleukin-6 [12]. These inflammatory mediators can accelerate plaque formation, destabilize existing plaques, and promote thrombosis - heightening the risk of acute coronary syndromes and ischemic stroke [18].

The recurrent surges in sympathetic activity and blood pressure associated with OSA also have deleterious effects on the myocardium. Chronic exposure to elevated afterload can induce pathological left ventricular hypertrophy, which impairs diastolic function and predisposes to heart failure with preserved ejection fraction. Moreover, the cyclical hypoxia-reoxygenation cycles characteristic of OSA have been linked to oxidative stress-mediated myocardial remodeling and fibrosis, further compromising cardiac function. Ultimately, the synergistic impacts of OSA on vascular, myocardial, and autonomic function coalesce to heighten the risk of a broad spectrum of cardiovascular & pulmonary diseases [8]. Early recognition and effective treatment of OSA may therefore be crucial in mitigating this heightened cardiovascular risk.

CONSEQUENCES ON THE CARDIOVASCULAR SYSTEM

Untreated obstructive sleep apnea has profound cardiovascular consequences that significantly impact patient health and quality of life. The pathophysiological mechanisms underlying these consequences are complex and involve a combination of intermittent hypoxia, sympathetic nervous system activation, and systemic inflammation with the understanding of these mechanisms being massively crucial for recognizing the risks associated with untreated OSAS and the importance of timely intervention [19].

Hypertension

One of the most significant cardiovascular consequences of untreated OSA is hypertension. Research indicates that approximately 50% of patients with essential hypertension also have sleep apnea, and untreated OSA can lead to the development of new-onset hypertension [20,21]. The intermittent hypoxia experienced during apneic episodes activates the sympathetic nervous system, resulting in increased catecholamine release. This activation leads to vasoconstriction and elevated blood pressure [22]. Additionally, the negative intrathoracic pressure generated during apneas can stimulate baroreceptors, further contributing to increased vascular resistance and hypertension. Studies have shown that patients with OSA have a higher prevalence of resistant hypertension, which is defined as blood pressure that remains elevated despite treatment with three or more antihypertensive medications.

Coronary Artery Disease

The risk of coronary artery disease (CAD) is markedly increased in individuals with untreated OSA [23]. The intermittent hypoxia and resultant oxidative stress contribute to endothelial dysfunction, a precursor to atherosclerosis. Endothelial cells are sensitive to changes in oxygen levels, and the repeated cycles of hypoxia and reoxygenation can lead to cellular injury and inflammation, promoting the development of atherosclerotic plaques. Furthermore, patients with OSA often exhibit increased levels of inflammatory markers, such as C-reactive protein (CRP), which are associated with a higher risk of cardiovascular events [24]. Studies have demonstrated that individuals with OSA have a significantly higher incidence of myocardial infarction compared to those without the condition, with some estimates suggesting that the risk of myocardial infarction is increased by 30-50% in patients with moderate to severe OSA [17,25].

Heart Failure

Heart failure is another serious consequence of untreated OSA. The condition can exacerbate existing heart failure or contribute to its development through several mechanisms. Intermittent hypoxia leads to increased left ventricular afterload due to elevated systemic vascular resistance, which

can impair cardiac output and lead to heart failure [26]. Additionally, the negative intrathoracic pressure generated during apneic episodes can cause hemodynamic instability, further straining the heart. Patients with OSA are also more likely to experience diastolic dysfunction, characterized by impaired filling of the heart during diastole, which is particularly concerning in the context of heart failure with preserved ejection fraction (HFpEF) [27]. Studies have shown that the prevalence of heart failure is significantly higher in patients with untreated OSAS, with estimates suggesting that up to 50% of patients with heart failure may have coexisting sleep apnea [25,28].

Arrhythmias

Arrhythmias, particularly atrial fibrillation (AF), are common in patients with untreated OSA. The combination of hypoxia, increased sympathetic tone, and atrial stretch due to negative intrathoracic pressure can trigger AF episodes [29]. Research indicates that the prevalence of AF is significantly higher in patients with untreated OSA compared to those without the condition, with some studies reporting rates as high as 21-74% in this population [29]. The presence of AF in patients with OSA is concerning because it increases the risk of thromboembolic events, including stroke. The mechanisms linking OSA to AF include the promotion of atrial remodeling due to chronic hypoxia and inflammation, which can lead to structural changes in the atria that predispose individuals to arrhythmias [30].

Stroke

The risk of stroke is significantly elevated in individuals with untreated OSA [31]. The mechanisms include the promotion of hypertension, increased platelet aggregation, and the potential for embolic events due to arrhythmias. Studies have shown that individuals with severe OSA have a higher incidence of both ischemic and hemorrhagic strokes, with some estimates suggesting that the risk of stroke is increased by 2-4 times in patients with untreated OSA compared to those without the condition [32]. The intermittent hypoxia associated with OSA can lead to increased levels of inflammatory markers and changes in coagulation profiles, further contributing to the risk of stroke. Additionally, the presence of comorbid conditions, such as hypertension and diabetes, often seen in patients with OSA, compounds the risk of cerebrovascular events [33].

The cardiovascular consequences of untreated OSA are extensive and multifaceted, affecting various aspects of heart health. The interplay of intermittent hypoxia, sympathetic activation, and inflammatory processes contributes to a range of serious health issues, including hypertension, coronary artery disease, heart failure, arrhythmias, and stroke which underscore the critical importance of timely diagnosis and effective treatment to mitigate these serious health risks and improve patient outcomes.

CONSEQUENCES ON THE PULMONARY SYSTEM

Untreated obstructive sleep apnea syndrome has significant pulmonary consequences that can lead to serious health complications. The interplay between sleep-disordered breathing and pulmonary function can exacerbate existing respiratory conditions and contribute to new pulmonary issues. Understanding these consequences is crucial for recognizing the risks associated with untreated OSA and the importance of timely intervention.

Intermittent Hypoxia

One of the primary pulmonary consequences of untreated OSA is intermittent hypoxia. During apneic episodes, the airway becomes obstructed, leading to periods of reduced oxygen saturation in the blood. This intermittent hypoxia can have several detrimental effects on pulmonary health. The repeated cycles of hypoxia and reoxygenation can cause oxidative stress, which damages lung tissue and promotes

inflammation. Over time, this can lead to structural changes in the lungs, including airway remodeling and increased airway resistance, which can exacerbate conditions such as asthma and chronic obstructive pulmonary disease (COPD) [34].

Pulmonary Hypertension

Intermittent hypoxia is also a significant contributor to the development of pulmonary hypertension. The hypoxic episodes experienced during sleep can lead to increased pulmonary artery pressure due to vasoconstriction of the pulmonary vasculature. This response is a compensatory mechanism aimed at redirecting blood flow to better-ventilated areas of the lung; however, chronic hypoxia can lead to maladaptive changes, including vascular remodeling and increased resistance in the pulmonary arteries. Studies have shown that patients with OSA are at a higher risk of developing pulmonary hypertension, which can lead to right heart strain and eventual right-sided heart failure if left untreated.

Chronic Obstructive Pulmonary Disease

There is a notable association between OSA and COPD. Patients with both conditions may experience exacerbated respiratory symptoms due to the combined effects of airway obstruction and sleep-disordered breathing. The presence of OSA in COPD patients can worsen nocturnal oxygen saturation and increase the risk of respiratory failure [24]. Research indicates that individuals with COPD who also have OSA experience more frequent exacerbations and have a higher risk of hospitalization compared to those with COPD alone. The overlap between these two conditions complicates management and necessitates a comprehensive approach to treatment.

Increased Risk of Respiratory Failure

Individuals with untreated OSA are at a higher risk for respiratory failure, particularly during sleep [37]. The combination of airway obstruction and impaired respiratory drive can lead to significant drops in oxygen saturation, necessitating emergency interventions in severe cases. This risk is particularly pronounced in patients with pre-existing respiratory conditions, such as COPD or asthma, where the added burden of OSA can lead to acute exacerbations and respiratory distress [17]. The potential for respiratory failure underscores the importance of monitoring and managing sleep apnea in patients with existing pulmonary conditions.

Pulmonary Edema

The negative intrathoracic pressure generated during apneic episodes can also lead to pulmonary edema, particularly in patients with pre-existing heart conditions. When the airway is obstructed, the pressure in the thoracic cavity decreases, which can cause fluid to shift from the bloodstream into the lung interstitium, resulting in pulmonary edema. This condition can exacerbate respiratory symptoms and lead to acute respiratory distress, requiring immediate medical attention. The presence of pulmonary edema in patients with OSA can complicate the clinical picture, making it essential for healthcare providers to recognize and address this potential complication.

Sleep-Related Breathing Disorders

OSA can coexist with other sleep-related breathing disorders, complicating the clinical picture. For instance, central sleep apnea may occur in patients with heart failure, further complicating management and increasing the risk of adverse outcomes. The presence of multiple sleep-related breathing disorders can lead to more severe hypoxemia and increased cardiovascular strain, necessitating a comprehensive evaluation and tailored treatment approach.

Long-Term Consequences

The long-term pulmonary consequences of untreated OSA can be severe. Chronic exposure to intermittent hypoxia can lead to permanent changes in lung function, including reduced lung compliance and

impaired gas exchange. Over time, these changes can contribute to the development of pulmonary fibrosis and other chronic lung diseases, further complicating the management of patients with OSA. Additionally, the increased risk of pulmonary hypertension and right heart failure can lead to significant morbidity and mortality in this population [33].

The pulmonary consequences of untreated OSA are extensive and multifaceted. The interplay of intermittent hypoxia, pulmonary hypertension, and the exacerbation of existing respiratory conditions can lead to serious health issues, including increased risk of respiratory failure, pulmonary edema, and chronic lung disease. These findings underscore the critical importance of timely diagnosis and effective treatment of OSA to mitigate these serious health risks and improve patient outcomes. Addressing OSA not only improves sleep quality but also has significant implications for overall pulmonary health and long-term well-being.

GENDER & AGE DIFFERENCES

The disparate impacts of untreated obstructive sleep apnea on the cardiovascular and pulmonary systems are particularly pronounced when considering gender and age-related differences. Emerging research has shed light on the unique vulnerabilities and variable disease trajectories observed in men versus women, as well as younger versus older individuals affected by this sleep disorder.

Gender Differences

Numerous studies have demonstrated that the cardiovascular consequences of untreated OSA are more severe in men compared to women. Gottlieb et al. found that the association between severe, untreated OSA and increased risk of stroke was substantially stronger in men than in women, even after accounting for potential confounding factors. This gender discrepancy may be attributable to inherent anatomical and hormonal differences that influence upper airway physiology and the propensity for sleep-disordered breathing [38].

The deleterious impact of untreated OSA on cardiac structure and function also appears to be more pronounced in men. Oliveira et al. reported that male OSA patients exhibited more advanced left ventricular hypertrophy and diastolic dysfunction compared to their female counterparts, even when matched for OSA severity and other comorbidities. These divergent cardiac remodeling patterns likely stem from gender-specific differences in the neurohumoral and metabolic responses to the intermittent hypoxia, sympathetic activation, and hemodynamic perturbations characteristic of untreated OSA.

Underlying mechanisms for these gender disparities remain an active area of investigation, but may involve sex-based variations in the regulation of vascular tone, inflammation, and oxidative stress pathways. Elucidating the biological underpinnings of these differential cardiovascular responses is crucial for developing targeted screening, diagnostic, and treatment strategies tailored to the unique needs of male and female OSA patients.

Additionally, emerging evidence suggests that untreated OSA may have a more detrimental impact on pulmonary function in men compared to women [38]. Studies have shown that male OSA patients exhibit greater reductions in vital capacity, forced expiratory volume, and diffusing capacity of the lung for carbon monoxide, indicating more pronounced respiratory impairments [37]. These gender-based differences in pulmonary mechanics and gas exchange may be attributed to disparities in upper airway anatomy, respiratory muscle function, and the burden of intermittent hypoxia on the lungs.

Furthermore, the gender-specific consequences of untreated OSA extend beyond the cardiovascular and pulmonary systems, also manifesting in distinct patterns of neurocognitive and behavioral impairments. Researchers have observed that men with untreated OSA are more susceptible to deficits in executive function,

attention, and vigilance, while women exhibit more pronounced deficits in memory and psychomotor speed [39]. These gender-based differences in the neurocognitive sequelae of untreated OSA underscore the need for individualized management approaches that consider the multifaceted, sex-specific impacts of this sleep disorder.

Age Differences

In addition to gender-related distinctions, the consequences of untreated OSA also appear to be significantly influenced by the patient's age. Older adults with untreated OSA seem to be at a heightened risk of adverse cardiovascular and pulmonary outcomes compared to their younger counterparts.

Peppard et al. reported that the association between OSA severity and hypertension was most pronounced in middle-aged and older adults, suggesting that the aging cardiovascular system may be particularly vulnerable to the detrimental hemodynamic effects of untreated sleep-disordered breathing [32]. Similarly, Redline et al. found that the elevated stroke risk conferred by severe, untreated OSA was greatest in older men, underscoring the compounded impact of advancing age and untreated OSA on cerebrovascular health [34].

These age-related disparities may be attributed to physiological changes that occur within the cardiovascular and respiratory systems as individuals grow older. With advancing age, the heart and lungs exhibit diminished functional reserve, reduced compliance, and increased susceptibility to the deleterious effects of intermittent hypoxia, sympathetic over-activation, and hemodynamic disturbances - all hallmarks of untreated OSA. Furthermore, the impact of untreated OSA on quality of life and functional status appears to be exacerbated in the elderly, with older adults experiencing more severe daytime sleepiness, fatigue, and cognitive impairment compared to younger patients.

Interestingly, the pulmonary consequences of untreated OSA also seem to be more pronounced in older individuals. Studies have shown that older OSA patients exhibit greater reductions in lung volumes, diffusing capacity, and arterial oxygenation compared to their younger counterparts. These age-related differences in respiratory mechanics and gas exchange may be attributed to the cumulative burden of intermittent hypoxia and the diminished physiological reserve of the aging lungs.

In summary, the extant literature highlights critical gender and age-related differences in the cardiovascular and pulmonary consequences of untreated obstructive sleep apnea. Male patients and older adults appear to be at a heightened risk of adverse outcomes, emphasizing the need for vigilant screening, diagnosis, and tailored management strategies to mitigate the deleterious health impacts of this highly prevalent sleep disorder across diverse patient populations. Elucidating the underlying biological mechanisms driving these disparities is crucial for informing personalized approaches to the clinical management of OSA and its associated comorbidities.

TREATMENT MECHANISMS & EVIDENCE

Given the substantial cardiovascular and pulmonary morbidity associated with untreated obstructive sleep apnea, a concerted effort has been made to elucidate the mechanisms by which various treatment modalities can effectively mitigate these adverse health outcomes. The two primary treatment approaches for OSA - continuous positive airway pressure (CPAP) therapy and surgical interventions - have each demonstrated the potential to reverse or attenuate the detrimental impacts of this sleep disorder on the cardiovascular and respiratory systems.

Continuous Positive Airway Pressure (CPAP) Therapy

CPAP, the gold-standard treatment for OSA, works by delivering a steady stream of air pressure to keep the upper airway patent during sleep, thereby preventing the cyclical

episodes of apnea and hypopnea that characterize this condition [34]. Numerous studies have demonstrated the cardiovascular and pulmonary benefits of CPAP therapy in OSA patients.

With respect to the cardiovascular system, regular CPAP use has been shown to significantly improve blood pressure control, reduce left ventricular hypertrophy, and attenuate the risk of adverse cardiovascular events, including myocardial infarction and stroke [36]. The mechanism by which CPAP exerts these cardioprotective effects is multifaceted, involving the mitigation of sympathetic hyperactivity, reduction in oxidative stress and inflammation, and restoration of normal vascular function and hemodynamics.

Importantly, the beneficial cardiovascular effects of CPAP appear to be most pronounced in patients who demonstrate good adherence to therapy. Barbe et al. found that OSA patients who used CPAP for at least 4 hours per night experienced a significant reduction in the risk of fatal and non-fatal cardiovascular events, whereas those with poor CPAP adherence did not derive the same level of cardiovascular risk reduction [36]. This underscores the importance of promoting long-term treatment compliance to maximize the cardioprotective benefits of CPAP.

The pulmonary benefits of CPAP therapy in OSA patients are equally well-documented. Studies have shown that regular CPAP use can improve lung volumes, gas exchange, and respiratory muscle function, thereby mitigating the deleterious respiratory consequences of untreated OSA [37]. The mechanism by which CPAP exerts these salutary effects on the pulmonary system likely involves the reduction in upper airway obstruction, alleviation of inspiratory muscle workload, and attenuation of the cyclic episodes of hypoxia and reoxygenation [32].

Furthermore, CPAP therapy has been shown to confer benefits beyond the cardiovascular and respiratory domains, positively impacting neurocognitive function, mood, and quality of life in OSA patients. Improved daytime alertness, concentration, and memory have been consistently reported with regular CPAP use, highlighting its multifaceted therapeutic potential [38].

Surgical Interventions

In addition to CPAP, various surgical techniques have also been employed to treat OSA, with the goal of permanently eliminating upper airway obstruction and alleviating the associated cardiovascular and pulmonary consequences.

Upper airway surgery, such as uvulopalatopharyngoplasty (UPPP) and maxillomandibular advancement (MMA), has demonstrated the capacity to improve cardiovascular outcomes in OSA patients. Studies have shown that surgical treatment can lead to reductions in blood pressure, improvements in left ventricular function, and attenuation of the risk of adverse cardiovascular events. The underlying mechanisms by which upper airway surgery confers these cardioprotective effects likely involve the elimination of the cyclical respiratory disturbances, normalization of sympathetic tone, and restoration of vascular function.

Interestingly, the pulmonary benefits of surgical interventions for OSA appear to be more variable and less well-defined compared to the cardiovascular outcomes. While some studies have reported improvements in lung volumes, gas exchange, and respiratory muscle function following surgical treatment, others have failed to demonstrate significant respiratory improvements. This variability may be attributable to factors such as patient selection, surgical technique, and the specific respiratory parameters assessed.

It is important to note that the efficacy of surgical interventions for OSA is heavily dependent on patient selection, surgical expertise, and postoperative adherence to adjunctive treatments (e.g., CPAP). Careful patient evaluation and individualized treatment planning are crucial to maximize the likelihood of successful long-term outcomes.

In summary, both CPAP therapy and surgical interventions have demonstrated the capacity to mitigate the cardiovascular and pulmonary consequences of obstructive sleep apnea. CPAP, the gold-standard treatment, has been shown to improve blood pressure control, cardiac function, and respiratory mechanics, with the magnitude of benefit closely linked to treatment adherence. Surgical approaches, while offering the potential for permanent anatomical correction, have exhibited more variable effects on the pulmonary system, underscoring the need for careful patient selection and interdisciplinary management strategies. Elucidating the precise mechanisms by which these treatment modalities exert their beneficial effects on the cardiovascular and respiratory systems is an active area of investigation, with the ultimate goal of optimizing the therapeutic management of this highly prevalent sleep disorder.

DISCUSSION

Obstructive sleep apnea is a highly prevalent sleep disorder with far-reaching consequences for the cardiovascular and pulmonary systems. The cyclical episodes of upper airway obstruction, intermittent hypoxia, and sympathetic activation that characterize untreated OSA can have a profound and deleterious impact on the heart, lungs, and overall health and well-being of affected individuals. As the evidence reviewed in this paper has demonstrated, the magnitude and trajectory of these adverse outcomes are heavily influenced by patient-specific factors, including gender and age.

The disproportionate burden of cardiovascular and respiratory morbidity borne by male and older adult OSA patients underscores the critical need for personalized approaches to screening, diagnosis, and treatment. Targeted assessment of an individual's unique anatomical, physiological, and behavioral characteristics should inform the development of tailored management strategies to optimize therapeutic outcomes across diverse patient populations.

For instance, the more pronounced cardiovascular consequences observed in men with untreated OSA may warrant a more aggressive approach to screening and early intervention in this demographic, incorporating advanced imaging techniques and biomarkers to facilitate timely diagnosis and initiation of appropriate treatment. Similarly, the exacerbated pulmonary impairments and heightened vulnerability of the aging cardiovascular and respiratory systems to the deleterious effects of untreated OSA may necessitate closer monitoring and more proactive management in older adult patients.

Beyond just gender and age, other individual-level factors such as genetic predisposition, comorbid conditions, and lifestyle behaviors may also significantly influence the phenotypic expression and trajectory of OSA and its associated comorbidities. Incorporating these multilayered determinants of disease risk and progression into personalized treatment algorithms holds great promise for improving long-term patient outcomes.

Importantly, the selection and optimization of therapeutic modalities, whether CPAP therapy or surgical interventions, must also be tailored to the unique needs and preferences of each patient. Maximizing treatment adherence and sustaining the beneficial cardiovascular and pulmonary effects of OSA management requires a patient-centered approach that addresses barriers to compliance, leverages technological innovations, and empowers individuals to take an active role in their care.

Furthermore, the development of novel, targeted pharmacotherapies represent an emerging frontier in the management of OSA and its multisystem consequences. Exploring the potential of pharmacological agents to modulate the underlying pathophysiological mechanisms driving cardiovascular and respiratory dysfunction in OSA patients, either as stand-alone treatments or in conjunction with existing interventions, may yield transformative advances in personalized disease management.

CONCLUSION

In conclusion, obstructive sleep apnea is a complex, multifaceted disorder with profound implications for cardiovascular and pulmonary health. Acknowledging and addressing the unique vulnerabilities and variable disease trajectories observed across diverse patient populations is crucial for optimizing therapeutic strategies and mitigating the debilitating impacts of this highly prevalent sleep disorder. A personalized, precision medicine approach, encompassing comprehensive assessment of individual risk factors, tailored treatment selection, and innovative pharmacological interventions, holds the promise of ushering in a new era of improved clinical outcomes and enhanced quality of life for those affected by obstructive sleep apnea.

Declaration by Authors

Ethical Approval: Not Required
Acknowledgement: None
Source of Funding: None
Conflict of Interest: No conflicts of interest declared.

REFERENCES

1. Park, J. G., Ramar, K., & Olson, E. J. (2011). Updates on definition, consequences, and management of obstructive sleep apnea. Mayo Clinic Proceedings, 86(6), 549–554; quiz 554-5. https://doi.org/10.4065/mcp.2010.0810
2. Stansbury, R. C., & Strollo, P. J. (2015). Clinical manifestations of sleep apnea. Journal of Thoracic Disease, 7(9), E298–E310. https://doi.org/10.3978/j.issn.2072-1439.2015.09.13
3. Dredla, B. K., & Castillo, P. R. (2019). Cardiovascular Consequences of Obstructive Sleep Apnea. Current Cardiology Reports, 21(11). https://doi.org/10.1007/s11886-019-1228-3
4. Ayas, N. T., Taylor, C. M., & Laher, I. (2016). Cardiovascular consequences of obstructive sleep apnea. Current Opinion in Cardiology, 31(6), 599–605. https://doi.org/10.1097/hco.0000000000000329
5. Knauert, M., Naik, S., Gillespie, M. B., & Kryger, M. (2015). Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. World Journal of Otorhinolaryngology-Head and Neck Surgery, 1(1), 17–27. https://doi.org/10.1016/j.wjorl.2015.08.001
6. Costanzo, M. R., Khayat, R., Ponikowski, P., Augostini, R., Stellbrink, C., Mianulli, M., & Abraham, W. T. (2015). Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure. Journal of the American College of Cardiology, 65(1), 72–84. https://doi.org/10.1016/j.jacc.2014.10.025
7. Morsy, N. E., Farrag, N. S., Zaki, N. F. W., Badawy, A. Y., Abdelhafez, S. A., El-Gilany, A.-H., El Shafey, M. M., Pandi-Perumal, S. R., Spence, D. W., & BaHammam, A. S. (2019). Obstructive sleep apnea: personal, societal, public health, and legal implications. Reviews on Environmental Health, 34(2), 153–169. https://doi.org/10.1515/reveh-2018-0068
8. Javaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., Polotsky, V. Y., Redline, S., & Somers, V. K. (2017). Sleep Apnea. Journal of the American College of Cardiology, 69(7), 841–858. https://doi.org/10.1016/j.jacc.2016.11.069
9. Young, T., Finn, L., Kim, H., & Peppard, P. E. (2016). Sleep Disordered Breathing and Risk of Stroke in the Wisconsin Sleep Cohort. Stroke, 47(5), 1269–1274. https://doi.org/10.1161/strokeaha.115.012210
10. Jordan, A. S., McSharry, D. G., & Malhotra, A. (2014). Adult obstructive sleep apnoea. The Lancet, 383(9918), 736–747. https://doi.org/10.1016/s0140-6736(13)60734-5
11. Ayas, N. T., White, D. P., Manson, J. E., Stampfer, M. J., Speizer, F. E., Malhotra, A., & Hu, F. B. (2003). A prospective study of sleep duration and coronary heart disease in women. Archives of Internal Medicine, 163(2), 205–209. https://doi.org/10.1001/archinte.163.2.205
12. Lo, G. H., Chang, W. P., Lin, C. L., Liang, J. T., & Sung, F. C. (2015). Increased Risk of Stroke among Patients with Untreated Obstructive Sleep Apnea: A Nationwide Population-Based Study. PloS One, 10(6), e0129618.

https://doi.org/10.1371/journal.pone.0129618

13. Mehra, R., Benjamin, E. J., Shahar, E., Gottlieb, D. J., Nawabit, R., Kirchner, H. L., ... Redline, S. (2006). Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. American Journal of Respiratory and Critical Care Medicine, 173(8), 910–916. https://doi.org/10.1164/rccm.200506-840OC
14. Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., & Badr, S. (1993). The Occurrence of Sleep-Disordered Breathing among Middle-Aged Adults. New England Journal of Medicine, 328(17), 1230–1235. https://doi.org/10.1056/nejm199304293281704
15. National Heart, Lung, and Blood Institute. (n.d.). What is Sleep Apnea? NHLBI. Retrieved October 23, 2023, from https://www.nhlbi.nih.gov/health-topics/sleep-apnea
16. Phillips, B. A., Berry, D. T., Anch, A. M., Dunbar, C. C., & Butt, Z. A. (2008). Effects of untreated obstructive sleep apnea and type of treatment on quality of life. Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine, 4(4), 356–361.
17. Punjabi, N. M., Caffo, B. S., Goodwin, J. L., Gottlieb, D. J., Newman, A. B., O'Connor, G. T., ... Shahar, E. (2009). Sleep-Disordered Breathing and Mortality: A Prospective Cohort Study. PLoS Med, 6(8), e1000132. https://doi.org/10.1371/journal.pmed.1000132
18. Durán-Cantolla, J., Aizpuru, F., Montserrat, J. M., Ballester, E., Terán-Santos, J., Jiménez, A., ... & Barbé, F. (2010). Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. BMJ, 341. https://doi.org/10.1136/bmj.c5991
19. Lopez-Jimenez, F., Sert Kuniyoshi, F. H., Gami, A., Somers, V. K. (2008). Obstructive sleep apnea: implications for cardiac and vascular disease: Part I: Obstructive sleep apnea: implications for management of arterial hypertension: expert panel recommendations. Journal of the American College of Cardiology, 51(20), 1953–1961. https://doi.org/10.1016/j.jacc.2008.02.005
20. Kraus, T., Georgi, P., Schöllgen, I., Schwarz, S., Wagner, S., Woehrle, H., & Bratzke, H. (2018). Internal medicine perspectives on sleep apnea: a review of pathophysiology, diagnosis and treatment. Deutsches Arzteblatt international, 115(21), 375–382. https://doi.org/10.3238/arztebl.2018.0375
21. Punjabi, N. M., Caffo, B. S., Goodwin, J. L., Gottlieb, D. J., Newman, A. B., O'Connor, G. T., ... Shahar, E. (2009). Sleep-Disordered Breathing and Mortality: A Prospective Cohort Study. PLoS Med, 6(8), e1000132. https://doi.org/10.1371/journal.pmed.1000132
22. Durán-Cantolla, J., Aizpuru, F., Montserrat, J. M., Ballester, E., Terán-Santos, J., Jiménez, A., ... & Barbé, F. (2010). Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. BMJ, 341. https://doi.org/10.1136/bmj.c5991
23. Lopez-Jimenez, F., Sert Kuniyoshi, F. H., Gami, A., Somers, V. K. (2008). Obstructive sleep apnea: implications for cardiac and vascular disease: Part I: Obstructive sleep apnea: implications for management of arterial hypertension: expert panel recommendations. Journal of the American College of Cardiology, 51(20), 1953–1961. https://doi.org/10.1016/j.jacc.2008.02.005
24. Kraus, T., Georgi, P., Schöllgen, I., Schwarz, S., Wagner, S., Woehrle, H., & Bratzke, H. (2018). Internal medicine perspectives on sleep apnea: a review of pathophysiology, diagnosis and treatment. Deutsches Arzteblatt international, 115(21), 375–382. https://doi.org/10.3238/arztebl.2018.0375
25. Knauert, M., Gillespie, M. B., Lacroix, H., Xia, Z., Mokhlesi, B., & Kryger, M. H. (2016). Nocturnal symptoms from obstructive sleep apnea and chronic insomnia: similarities and differences. CHEST, 150(4), 944-953.
26. Terán-Santos, J., Jiménez-Gómez, A., Cordero-Guevara, J., & The Cooperative Group Burgos-Santander. (1999). The association between sleep apnea and the risk of traffic accidents. New England Journal of Medicine, 340(11), 847-851.
27. Sharma, S., Agrawal, S., Damodaran, D., Sreenivas, V., Kadhiravan, T., Lakshmy, R., ... Jindal, S. K. (2011). CPAP for the metabolic syndrome in patients with

obstructive sleep apnea. New England Journal of Medicine, 365(24), 2277–2286. https://doi.org/10.1056/nejmoa1014756
28. Kraiczi, H., Hedner, J., Peker, Y., & Carlson, J. (2000). Increased Arousal Propensity in Sleep Apnea–Implications for Risk of Hypertension. Sleep, 23(6), 823–830. https://doi.org/10.1093/sleep/23.6.823
29. Yaggi, H. K., Concato, J., Kernan, W. N., Lichtman, J. H., Brass, L. M., & Mohsenin, V. (2005). Obstructive sleep apnea as a risk factor for stroke and death. New England Journal of Medicine, 353(19), 2034–2041. https://doi.org/10.1056/nejmoa043104
30. Morgenthaler, T. I., Kagramanov, V., Hanak, V., & Decker, P. A. (2006). Complex sleep apnea syndrome: Is it a unique clinical syndrome? Sleep, 29(9), 1203–1209. https://doi.org/10.1093/sleep/29.9.1203
31. Peppard, P. E., Young, T., Barnet, J. H., Palta, M., Hagen, E. W., & Hla, K. M. (2013). Increased prevalence of sleep-disordered breathing in adults. American Journal of Epidemiology, 177(9), 1006–1014. https://doi.org/10.1093/aje/kws342
32. Epstein, L. J., Kristo, D., Strollo, P. J., Friedman, N., Malhotra, A., Patil, S. P., ... & Weinstein, M. D. (2009). Clinical guidelines for the evaluation, management, and long-term care of obstructive sleep apnea in adults. Journal of Clinical Sleep Medicine, 5(3), 263–276. https://doi.org/10.5664/jcsm.27497
33. Tasali, E., Mokhlesi, B., & Van Cauter, E. (2008). Obstructive sleep apnea and type 2 diabetes: Interacting epidemics. Chest, 133(2), 496–506. https://doi.org/10.1378/chest.07-0828
34. Somers, V. K., White, D. P., Amin, R., Abraham, W. T., Costa, F., Culebras, A., ... & Young, T. (2008). Sleep apnea and cardiovascular disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement. Circulation, 118(10), 1080–1111. https://doi.org/10.1161/CIRCULATIONAHA.107.189420
35. Javaheri, S., & Redline, S. (2017). Sleep, slow-wave sleep, and blood pressure. Hypertension, 70(5), 824–826. https://doi.org/10.1161/HYPERTENSIONAHA.117.09978
36. Ryan, S., Ward, S., & Nolan, G. M. (2009). Sleep-disordered breathing and cardiovascular disease: A review of mechanisms and molecular pathways. Chest Journal, 136(4), 1047–1055. https://doi.org/10.1378/chest.08-1996
37. Redline, S., Yenokyan, G., Gottlieb, D. J., Shahar, E., O'Connor, G. T., Resnick, H. E., ... & Punjabi, N. M. (2010). Obstructive sleep apnea-hypopnea and incident stroke: The sleep heart health study. American Journal of Respiratory and Critical Care Medicine, 182(2), 269–277. https://doi.org/10.1164/rccm.200911-1746OC
38. Punjabi, N. M. (2008). The epidemiology of adult obstructive sleep apnea. Proceedings of the American Thoracic Society, 5(2), 136–143. https://doi.org/10.1513/pats.200709-155MG
39. Javaheri, S., & Javaheri, S. (2013). Obstructive sleep apnea, intermittent hypoxia, and lung inflammation: Translational approaches to autonomic dysfunction and cardiovascular outcomes. Current Hypertension Reports, 15(5), 514–523. https://doi.org/10.1007/s11906-013-0380-1

How to cite this article: Joseph White, Redah Essul, Gabriela Kennedy, Laxman Reddy Nadithe, Namani Satyanarayana, Paripelli Sunitha et.al. Consequences of untreated sleep apnea on the cardiovascular and pulmonary systems: a systematic review. *International Journal of Research and Review*. 2025; 12(2): 380-392. DOI: *10.52403/ijrr.20250245*

******